Chicago Equity Partners LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 37.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,105 shares of the company’s stock after purchasing an additional 4,965 shares during the quarter. Chicago Equity Partners LLC’s holdings in Eli Lilly and were worth $1,401,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Exane Derivatives raised its position in Eli Lilly and by 2,838.2% in the 4th quarter. Exane Derivatives now owns 18,687 shares of the company’s stock valued at $1,578,000 after buying an additional 18,051 shares during the last quarter. OppenheimerFunds Inc. raised its position in Eli Lilly and by 8.1% in the 4th quarter. OppenheimerFunds Inc. now owns 43,699 shares of the company’s stock valued at $3,690,000 after buying an additional 3,257 shares during the last quarter. Lazard Asset Management LLC raised its position in Eli Lilly and by 0.8% in the 4th quarter. Lazard Asset Management LLC now owns 826,865 shares of the company’s stock valued at $69,835,000 after buying an additional 6,437 shares during the last quarter. MetLife Investment Advisors LLC acquired a new stake in Eli Lilly and in the 4th quarter valued at approximately $25,319,000. Finally, Westpac Banking Corp raised its position in Eli Lilly and by 10.9% in the 4th quarter. Westpac Banking Corp now owns 93,869 shares of the company’s stock valued at $7,928,000 after buying an additional 9,250 shares during the last quarter. 78.32% of the stock is currently owned by institutional investors.
Eli Lilly and opened at $81.66 on Friday, MarketBeat.com reports. The company has a quick ratio of 1.01, a current ratio of 1.41 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $89.23 billion, a price-to-earnings ratio of 19.08, a P/E/G ratio of 1.42 and a beta of 0.26. Eli Lilly and Company has a twelve month low of $81.19 and a twelve month high of $81.89.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be paid a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $2.25 annualized dividend and a dividend yield of 2.76%. Eli Lilly and’s dividend payout ratio is currently 52.57%.
In other news, insider Donald A. Zakrowski sold 876 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $77.55, for a total transaction of $67,933.80. Following the completion of the transaction, the insider now directly owns 4,130 shares in the company, valued at approximately $320,281.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Donald A. Zakrowski sold 860 shares of Eli Lilly and stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $76.50, for a total value of $65,790.00. The disclosure for this sale can be found here. Insiders have sold a total of 361,472 shares of company stock valued at $29,328,215 over the last quarter. 0.11% of the stock is currently owned by corporate insiders.
A number of equities research analysts recently issued reports on LLY shares. Credit Suisse Group lowered Eli Lilly and from a “neutral” rating to an “underperform” rating and set a $82.00 target price on the stock. in a research report on Monday, January 22nd. BMO Capital Markets lifted their target price on Eli Lilly and from $73.00 to $74.00 and gave the company an “underperform” rating in a research report on Thursday, February 1st. Bank of America dropped their target price on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a research report on Thursday, February 1st. JPMorgan Chase set a $105.00 target price on Eli Lilly and and gave the company a “buy” rating in a research report on Monday, February 26th. Finally, Jefferies Group set a $93.00 target price on Eli Lilly and and gave the company a “buy” rating in a research report on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $93.21.
Eli Lilly and Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.